View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAnanda Pharma 将来の成長Future 基準チェック /06現在、 Ananda Pharmaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長10.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Nov 24Ananda Pharma Plans to Delist from Aquis Stock ExchangeAnanda Pharma PLC Board proposes to de-list the company from Aquis Stock Exchange and become a private company, citing the cost of maintaining a listing and a dearth of liquidity for its shares. Ananda Pharma calls a general meeting of shareholders for December 12 to approve the plan. "As you know I have funded Ananda with more than GBP 10 million over the past 8 years," explains Executive Chair Charles Morgan. "Despite our best efforts, we have not managed to gain the funding support of the public markets, so we intend to delist the company while we progress MRX1 development and our clinical trials. This move will save Ananda around GBP 500,000 per annum".Board Change • Oct 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Clive Page was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jul 31Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025. Location: the offices of arch law, level 2, huckletree, 8 bishopsgate, london, ec2n 4bq United KingdomNew Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 49% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£860k). Earnings have declined by 61% per year over the past 5 years. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Revenue is less than US$1m (UK£764 revenue, or US$933). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (UK£18.3m market cap, or US$22.3m).お知らせ • Dec 11Ananda Developments Plc has completed a Follow-on Equity Offering in the amount of £0.15 million.Ananda Developments Plc has completed a Follow-on Equity Offering in the amount of £0.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 42,857,142 Price\Range: £0.0035New Risk • Nov 01New major risk - Negative shareholders equityThe company has negative equity. Total equity: -UK£860k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£860k). Earnings have declined by 61% per year over the past 5 years. Revenue is less than US$1m (UK£764 revenue, or US$987). Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (UK£11.8m market cap, or US$15.2m).お知らせ • Oct 07Ananda Developments Plc Announces Appointment of Professor Marie Fallon to Scientific Advisory BoardAnanda Developments Plc announced the appointment of Professor Marie Fallon has agreed to join the Company's Scientific Advisory Board to provide the Company with expert technical advice and guidance. The SAB is Chaired by Professor Clive Page, a non-executive director of Ananda Developments plc and it held its first meeting in Edinburgh in May 2024. Prof. Fallon is also the lead investigator for Ananda's Phase II study investigating the pain relieving effects of MRX1 in patients with Chemotherapy Induced Peripheral Neuropathy. Marie Fallon (MD FRCP(Glas) FRCP(E) MRCGP DCH DRCOG). Marie is a Professor of Palliative Medicine at the University of Edinburgh and is an Honorary Consultant in Palliative Medicine based at the Edinburgh Cancer Centre. Marie has played a significant role in research, leading both national and international research studies around pain and cachexia in cancer patients. Marie has led the development of international palliative care guidelines such as ESMO for cancer pain and ASCO for cachexia. Marie has been Joint Editor of four editions of the Oxford Textbook of Palliative Medicine which is the reference textbook in the specialty. Prof. Fallon has edited several other books and sits on numerous grant committees, as well as being an editorial board member of the BMJ Supportive and Palliative Care journal. Finally, of note, much of Marie's recent and current research relates to Low and Middle Income Countries (LMICs), where she is seeking to address the issue of poor opioid availability in LMICs.New Risk • Sep 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 25% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 54% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (UK£12.6m market cap, or US$16.6m).お知らせ • Jul 17Ananda Developments Plc, Annual General Meeting, Aug 09, 2024Ananda Developments Plc, Annual General Meeting, Aug 09, 2024. Location: the offices of shakespeare martineau llp, 6th floor, 60 gracechurch street, ec3v, london United KingdomNew Risk • May 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended July 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported July 2023 fiscal period end). Market cap is less than US$100m (UK£9.07m market cap, or US$11.4m).New Risk • Nov 01New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended July 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported July 2022 fiscal period end). Shareholders have been substantially diluted in the past year (251% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (UK£7.91m market cap, or US$9.60m). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).お知らせ • Aug 01Ananda Developments Plc, Annual General Meeting, Aug 24, 2023Ananda Developments Plc, Annual General Meeting, Aug 24, 2023, at 13:00 Coordinated Universal Time. Location: the offices of Shakespeare Martineau Llp, 6th Floor 60 Gracechurch Street, London, EC3V 0HR London United KingdomBoard Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Executive Departure • Aug 26Non-Executive Director Peter Redmond has left the companyOn the 23rd of August, Peter Redmond's tenure as Non-Executive Director ended after 2.2 years in the role. As of June 2021, Peter still personally held 8.69m shares (UK£67k worth at the time). Peter is the only executive to leave the company over the last 12 months.お知らせ • Jul 15Ananda Developments Plc announced that it expects to receive £0.55 million in fundingAnanda Developments Plc (OFEX:ANA) announced a private placement of convertible loan notes for gross proceeds of £550,000 on July 14, 2021. The transaction will include participation from returning investors. The convertible loan notes will bear interest at a rate of 12.5% per annum and will mature in 2 years. The notes will be convertible into ordinary shares in the company at a price of £0.01 per share. On the same day, the company received £350,000 in its first tranche. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Ananda Pharma は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OFEX:ANA - アナリストの将来予測と過去の財務データ ( )GBP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数7/31/20250-5N/AN/AN/A4/30/20250-4N/AN/AN/A1/31/20250-4-1-1N/A10/31/20240-5N/AN/AN/A7/31/20240-6N/AN/AN/A4/30/20240-6N/AN/AN/A1/31/2024N/A-6-1-1N/A10/31/2023N/A-4N/AN/AN/A7/31/2023N/A-2N/AN/AN/A4/30/2023N/A-2N/AN/AN/A1/31/2023N/A-100N/A10/31/2022N/A-1N/AN/AN/A7/31/2022N/A-1N/AN/AN/A4/30/2022N/A-1N/AN/AN/A1/31/2022N/A-1N/AN/AN/A10/31/2021N/A-1N/AN/AN/A7/31/2021N/A-1N/AN/AN/A4/30/2021N/A-1N/AN/AN/A1/31/2021N/A0N/AN/AN/A10/31/2020N/A0N/AN/AN/A7/31/2020N/A000N/A4/30/2020N/A000N/A1/31/2020N/A0-1-1N/A10/31/2019N/A0-1-1N/A7/31/2019N/A-1-1-1N/A4/30/2019N/A-1N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ANAの予測収益成長が 貯蓄率 ( 3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ANAの収益がUK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ANAの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ANAの収益がUK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ANAの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ANAの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/12/23 17:25終値2025/12/19 00:00収益2025/07/31年間収益2025/01/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ananda Pharma Plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Nov 24Ananda Pharma Plans to Delist from Aquis Stock ExchangeAnanda Pharma PLC Board proposes to de-list the company from Aquis Stock Exchange and become a private company, citing the cost of maintaining a listing and a dearth of liquidity for its shares. Ananda Pharma calls a general meeting of shareholders for December 12 to approve the plan. "As you know I have funded Ananda with more than GBP 10 million over the past 8 years," explains Executive Chair Charles Morgan. "Despite our best efforts, we have not managed to gain the funding support of the public markets, so we intend to delist the company while we progress MRX1 development and our clinical trials. This move will save Ananda around GBP 500,000 per annum".
Board Change • Oct 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Clive Page was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 31Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025. Location: the offices of arch law, level 2, huckletree, 8 bishopsgate, london, ec2n 4bq United Kingdom
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 49% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£860k). Earnings have declined by 61% per year over the past 5 years. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Revenue is less than US$1m (UK£764 revenue, or US$933). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (UK£18.3m market cap, or US$22.3m).
お知らせ • Dec 11Ananda Developments Plc has completed a Follow-on Equity Offering in the amount of £0.15 million.Ananda Developments Plc has completed a Follow-on Equity Offering in the amount of £0.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 42,857,142 Price\Range: £0.0035
New Risk • Nov 01New major risk - Negative shareholders equityThe company has negative equity. Total equity: -UK£860k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£860k). Earnings have declined by 61% per year over the past 5 years. Revenue is less than US$1m (UK£764 revenue, or US$987). Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (UK£11.8m market cap, or US$15.2m).
お知らせ • Oct 07Ananda Developments Plc Announces Appointment of Professor Marie Fallon to Scientific Advisory BoardAnanda Developments Plc announced the appointment of Professor Marie Fallon has agreed to join the Company's Scientific Advisory Board to provide the Company with expert technical advice and guidance. The SAB is Chaired by Professor Clive Page, a non-executive director of Ananda Developments plc and it held its first meeting in Edinburgh in May 2024. Prof. Fallon is also the lead investigator for Ananda's Phase II study investigating the pain relieving effects of MRX1 in patients with Chemotherapy Induced Peripheral Neuropathy. Marie Fallon (MD FRCP(Glas) FRCP(E) MRCGP DCH DRCOG). Marie is a Professor of Palliative Medicine at the University of Edinburgh and is an Honorary Consultant in Palliative Medicine based at the Edinburgh Cancer Centre. Marie has played a significant role in research, leading both national and international research studies around pain and cachexia in cancer patients. Marie has led the development of international palliative care guidelines such as ESMO for cancer pain and ASCO for cachexia. Marie has been Joint Editor of four editions of the Oxford Textbook of Palliative Medicine which is the reference textbook in the specialty. Prof. Fallon has edited several other books and sits on numerous grant committees, as well as being an editorial board member of the BMJ Supportive and Palliative Care journal. Finally, of note, much of Marie's recent and current research relates to Low and Middle Income Countries (LMICs), where she is seeking to address the issue of poor opioid availability in LMICs.
New Risk • Sep 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 25% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 54% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (UK£12.6m market cap, or US$16.6m).
お知らせ • Jul 17Ananda Developments Plc, Annual General Meeting, Aug 09, 2024Ananda Developments Plc, Annual General Meeting, Aug 09, 2024. Location: the offices of shakespeare martineau llp, 6th floor, 60 gracechurch street, ec3v, london United Kingdom
New Risk • May 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended July 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported July 2023 fiscal period end). Market cap is less than US$100m (UK£9.07m market cap, or US$11.4m).
New Risk • Nov 01New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended July 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported July 2022 fiscal period end). Shareholders have been substantially diluted in the past year (251% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (UK£7.91m market cap, or US$9.60m). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).
お知らせ • Aug 01Ananda Developments Plc, Annual General Meeting, Aug 24, 2023Ananda Developments Plc, Annual General Meeting, Aug 24, 2023, at 13:00 Coordinated Universal Time. Location: the offices of Shakespeare Martineau Llp, 6th Floor 60 Gracechurch Street, London, EC3V 0HR London United Kingdom
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Executive Departure • Aug 26Non-Executive Director Peter Redmond has left the companyOn the 23rd of August, Peter Redmond's tenure as Non-Executive Director ended after 2.2 years in the role. As of June 2021, Peter still personally held 8.69m shares (UK£67k worth at the time). Peter is the only executive to leave the company over the last 12 months.
お知らせ • Jul 15Ananda Developments Plc announced that it expects to receive £0.55 million in fundingAnanda Developments Plc (OFEX:ANA) announced a private placement of convertible loan notes for gross proceeds of £550,000 on July 14, 2021. The transaction will include participation from returning investors. The convertible loan notes will bear interest at a rate of 12.5% per annum and will mature in 2 years. The notes will be convertible into ordinary shares in the company at a price of £0.01 per share. On the same day, the company received £350,000 in its first tranche.